Better Health for All

Redhill Biopharma's entire product portfolio is dedicated to treating serious diseases, including H. pylori infection, severe COVID-19, Crohn's disease, and various cancers, demonstrating revolutionary health benefits. Talicia, for instance, achieved 83.8% eradication rates for H. pylori in the ITT population, which is linked to a ~75% decreased risk of gastric cancer.

Opaganib showed a 70.2% mortality benefit and 34% faster recovery in hospitalized severe COVID-19 patients. RHB-107 demonstrated a 100% reduction in hospitalization and an 87.8% reduction in severe symptoms in non-hospitalized COVID-19 patients. The company's products are generally well-tolerated, with Opaganib showing safety in over 470 individuals and RHB-107 in approximately 200 patients. However, Talicia has several contraindications and potential serious adverse reactions, including hypersensitivity and fetal harm, and Opaganib may cause neuropsychiatric toxicity. The company provides access programs for Talicia, with 7 out of 10 commercial lives and 6 out of 10 government lives covered, including a $0 copay for 15 million Californian Medi-Cal patients. Redhill's products address significant global health challenges, such as H. pylori affecting over 50% of the world population and COVID-19. The company actively participates in global health crisis response, developing Opaganib for Ebola and RHB-107 for COVID-19, with U.S. government support. Redhill's R&D expenses were $1.6 million in 2024, a decrease from $3.5 million in 2023. The company's expanded access policy allows for investigational drugs for serious conditions, but several products are not currently available under this policy. While the company provides safety information and forward-looking statements, it does not provide comprehensive public data on health risks or benefits beyond regulatory requirements. The company's patent protection for products like Talicia extends to 2034 and RHB-204 to 2041, with no evidence of flexible patent policies for global health needs. The company's clinical trials adhere to ethical standards, including informed consent.

Honest & Fair Business

The company has a formal whistleblower protection policy that allows associates to report suspected unethical conduct anonymously or not, via email or a confidential hotline.

The policy commits to confidentiality and non-retaliation, and states that investigations must be completed within 7 working days of receiving a report. The Chairman of the Audit Committee is responsible for assigning an executive to investigate, with legal counsel documenting the process, and reporting to the Audit Committee and Board within the first quarter after the report. Regarding board independence, all directors are independent except for two, Dror Ben-Asher and Rick D. Scruggs. For anti-corruption, the company outlines a compliance program for U.S. operations, specifically addressing California requirements, which includes written policies and procedures for interactions with healthcare professionals, a U.S. Compliance Officer and Committee, annual compliance training, and auditing/monitoring procedures. The company declares substantial compliance with its Comprehensive Compliance Program and California Health & Safety Code sections 119400-119402 as of November 1, 2022.

Kind to Animals

The company utilizes in vitro studies for specific purposes such as viral inhibition and potency, demonstrating some use of non-animal methods.

However, it heavily relies on in vivo (animal) studies for drug development, particularly for efficacy under the FDA Animal Rule. The company's policy explicitly leverages the FDA Animal Rule, which allows for pivotal animal model efficacy studies when human trials are not ethical or feasible. This rule is being used for the development of opaganib as a medical countermeasure for conditions like Acute Radiation Syndrome and phosgene inhalation injury. The company has conducted eight U.S. government-funded preclinical in vivo studies and multiple additional in vivo studies, indicating a significant volume of animal testing.

No War, No Weapons

Redhill Biopharma's core business is biopharmaceuticals, and there is no evidence of revenue derived from arms or defense contracts.

However, the company is developing Opaganib and RHB-107 as medical countermeasures for viral infections, oncology, Ebola, COVID-19, and potential nuclear, chemical, or radiological exposure due to pandemics, disease outbreaks, accidents, warfare, or terrorism. These products are considered dual-use technology, with collaborations with entities like the U.S. Army and BARDA for countermeasure development. The company has also stated it is in discussions regarding potential divestment of certain assets and/or commercial operations, but no specific details or timelines for a formal conflict divestment policy are provided.

Respect for Cultures & Communities

The provided articles, including company website content, financial results, clinical trial announcements, a careers page, and a corporate governance document, do not contain any specific, concrete data points or information relevant to Redhill Biopharma Ltd.'s respect for cultures and communities.

Therefore, no KPIs can be scored based on the evidence provided.

Safe & Smart Tech

Redhill Biopharma Ltd. has reported no unauthorized data use incidents.

The company's privacy policy outlines user rights, including access, modification, opposition, erasure, and portability of their data. It also describes data retention policies and states compliance with GDPR and other data protection laws. However, no specific details on the implementation or metrics for these practices are provided.